<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02405780</url>
  </required_header>
  <id_info>
    <org_study_id>FKB327-003</org_study_id>
    <nct_id>NCT02405780</nct_id>
  </id_info>
  <brief_title>A Study to Compare FKB327 Long-term Safety, Efficacy and Immunogenicity With Humira® in Rheumatoid Arthritis Patients</brief_title>
  <acronym>ARABESC-OLE</acronym>
  <official_title>An Open-label Extension Study to Compare the Long-term Efficacy, Safety, Immunogenicity and Pharmacokinetics of FKB327 and Humira® in Patients With Rheumatoid Arthritis on Concomitant Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujifilm Kyowa Kirin Biologics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujifilm Kyowa Kirin Biologics Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the long-term safety, effectiveness and immunogenicity
      of FKB327 in comparison to Humira® in rheumatoid arthritis patients who have completed study
      FKB327-002 and have inadequate disease control on methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The first period of this extension study was an open label, randomised, comparative, multi
      centre, 2 arm extension Phase 3 study in patients with RA who were taking a stable dose of
      MTX and who had continued from the preceding Study FKB327-002 (NCT02260791). The transition
      from Study FKB327-002 was ideally to occur without interruption: the Week 24 visit of Study
      FKB327-002 was to be on the same day as the Week 0 visit of Study FKB327-003. Patients who
      had received FKB327 in Study FKB327-002 received FKB327 or Humira in a 2:1 ratio and patients
      who had received Humira in Study FKB327-002 received Humira or FKB327 in a 2:1 ratio (Period
      I). The second period of the study was an open label, single arm extension in which all
      patients received FKB327 treatment from Week 30 to Week 76 (Period II), followed by a 4 week
      Follow up period.

      Clinic visits were scheduled for Weeks 0, 2, 4, 8, 12, 24, 30, 32, 34, 42, 54, 66, 76, and
      80. The patient or carer was allowed to administer interim doses of study drug at home every
      other week (eow) between clinic visits.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 10, 2015</start_date>
  <completion_date type="Actual">January 18, 2018</completion_date>
  <primary_completion_date type="Actual">January 18, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events as a Measure of Safety Per Treatment Group in Period I</measure>
    <time_frame>Period I: from Week 0 up until Week 30;</time_frame>
    <description>Period I: Patients were carefully monitor for Adverse Events from signing of informed consent until week 30 and thereafter during Period II of the study. For patients who discontinued early, a follow-up period of 4 weeks was added to the Early Termination Visit.
The investigator actively asked the patients for Adverse Events. Patients spontaneously reported Adverse Events to the Investigator during clinic visits or in between visits.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Adverse Events as a Measure of Safety in Period II - Single Treatment Period</measure>
    <time_frame>Period II: from Week 30 up to Week 80</time_frame>
    <description>From week 30 all subjects were transferred to receive FKB327 treatment. Adverse Events were contentiously monitored and recorded during Period II. For patients discontinuing the study prematurely, a follow-up period of 4 weeks was added to the Early Termination Visit. The data for Period II is based on the number of patients in the Safety Analysis Set that entered Period II.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Serious Adverse Events as a Measure of Safety Per Treatment Group in Period I</measure>
    <time_frame>Period I: from Week 0 up until Week 30</time_frame>
    <description>A Serious Adverse Event (SAE) was defined in the Protocol as: Death; or a Life-threatening Adverse Event (AE); Inpatient Hospitalization; Persistant or significant disability or incapacity; A congenital anomaly/birth defect; An important medical event that may not have resulted in death, have been life-threatening, or required hospitalization, but may have jeopardized the patient and may have required medical intervention to prevent 1 of the outcomes listed in this definition.
SAEs were followed until resolution, the investigator confirmed the event was unlikely to resolve or the patient was recorded as lost to follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Serious Adverse Events as a Measure of Safety in Period II - Single Treatment Period</measure>
    <time_frame>Period II: from Week 30 up to Week 80</time_frame>
    <description>Period II: at week 30 all patients were transferred to receive FKB327.
Each subject was counted once within each System Organ Class (SOC) and Preferred Term (PT). Death defined as a fatal outcome of a (S)AE.
SAEs were followed until resolution, the investigator confirmed the event was unlikely to resolve or the patient was lost to follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs as a Measure of Safety - Systolic Blood Pressure</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>Systolic Blood Pressure is part of Vital Signs which were part of the subject safety evaluations. Systolic Blood Pressure was measured at the following time-points: Week 0, Week 4, Week 8, Week 12, Week 24 and Week 80/End o Study (EOS). Systolic Blood Pressure with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs as a Measure of Safety - Diastolic Blood Pressure</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>Diastolic Blood Pressure is part of Vital Signs which were part of the subject safety evaluations. Diastolic Blood Pressure was measured at the following time-points: Week 0, Week 4, Week 8, Week 12, Week 24 and Week 80/End o Study (EOS). Diastolic Blood Pressure with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit measured.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs as a Measure of Safety - Pulse Rate</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>Pulse rate is part of Vital Signs which were part of the subject safety evaluations. Pulse rate was measured at the following time-points: Weeks 0, 4, 8, 12, 24 and 80/End of Study (EOS). Pulse Rate with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Vital Signs as a Measure of Safety - Temperature Measurements</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>Temperature measurements forms part of the vital signs which was one of the continuous safety measurements for the study primary endpoint.
Temperature was measured at week 0, week 4, week 8, week 12, week 24 and at week 80 or at End of Study (EOS).
Temperature with change from Baseline_002 were summarized by treatment sequence over the whole study period.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administration at Week 0 from Study FKB327-002 (NCT02260791).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Summary of Most Common Clinical Significant Laboratory Parameters Reported as Adverse Events (Reported by ≥1% of the Patients)</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>Clinical Laboratory tests for hematology and serum chemistry were performed by the sites and analysed at a Central Laboratory. Urine dip-stick tests were performed by the sites. Laboratory samples were taken at the following time-points (weeks): 0; 4; 8; 12; 24; 30; 42; 54; 66; 76 and 80/End of Study (EOS). Each result outside its normal range was review and assessed by the investigator whether or not it was Clinically Significant (CS) or Not Clinically Significant (NCS) CS laboratory abnormalities were recorded as AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Disease Activity Score 28 Based on C Reactive Protein (DAS28 CRP) Score Compared to Baseline as a Measure of Efficacy</measure>
    <time_frame>From Week 0 of FKB327-002 to Week 80</time_frame>
    <description>The DAS28 score is a combined index that has been developed to measure the disease activity in patients with Rheumatoid arthritis (RA) and has been extensively validated for the use in clinical studies. The DAS28-CRP assessment involved evaluating the number of tender (TJC) and the swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (Visual analogue scale (VAS) from 0-100, very well to extremely bad). The individual results are summarized using a formula. DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity.
During the FKB327-003 study for Period I and Period II the DAS28-CRP score was compared to Baseline in study FKB327-002 (NCT02260791).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 20 (ACR20) Response Rates From Baseline as a Measure of Efficacy</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>An ACR20 response means that the patient achieved a 20% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and a 20% improvement in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein, CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 50 (ACR50) Response Rates From Baseline as a Measure of Efficacy</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>An ACR50 response means that the patient achieved a 50% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein, CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American College of Rheumatology 70 (ACR70) Response Rates From Baseline as a Measure of Efficacy</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>An ACR70 response means that the patient achieved a 70% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein,CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Patients Developing Anti-drug Antibodies (ADAs)</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>Blood samples for assessment of Anti-Drug antibodies (ADA) were collected prior to dosing (trough samples) at Baseline (Week 0) and at Weeks 12, 24, 30, 54, 76 and 80/EOS.
All ADA activity was listed and summarized for each treatment sequence by time point during the overall treatment period as well as by treatment group for each period (Period I and Period II). Descriptive statistics included absolute counts (n) and percentage (%).</description>
  </other_outcome>
  <other_outcome>
    <measure>Trough Adalimumab Concentration</measure>
    <time_frame>From Week 0 to Week 80</time_frame>
    <description>Blood samples for the quantification of adalimumab concentration in serum were collected prior to dosing (trough samples) at Baseline (Week 0), and at weeks 12, 24 , 30, 54, 76 and 80/EOS.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">645</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>FKB327</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Humira®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive the drug 40 mg every other week by subcutaneous injection. The treatment period may continue for 76 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FKB327</intervention_name>
    <description>Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.</description>
    <arm_group_label>FKB327</arm_group_label>
    <other_name>adalimumab biosimilar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Humira®</intervention_name>
    <description>Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.</description>
    <arm_group_label>Humira®</arm_group_label>
    <other_name>adalimumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has completed the Week 24 visit procedures of Study FKB327-002 (NCT02260791)
             and are continuing with methotrexate

          2. In the investigator's opinion, the patient showed a clinical response to treatment
             during Study FKB327-002 (NCT02260791)

        Exclusion Criteria:

          1. Patient has evidence of a serious adverse event (SAE) ongoing from Study FKB327-002

          2. Patient has presence of active and/or untreated latent tuberculosis (TB)

        Other Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Josephine Glover, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Coephycient Pharmaceutical Consultancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Catherines</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois-Rivieres</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osorno</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puerto Varas</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site G</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site M</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hlucin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site U</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uherske Hradiste</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zlin</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ratingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site B</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site M</name>
      <address>
        <city>Arequipa</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site CA</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site CH</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site PA</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site S</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site D</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site R</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site KL</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site KR</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site P</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site RH</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oradea</city>
        <state>Bihor</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sfantu Gheorghe</city>
        <state>Covasna</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site C</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site R</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site T</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ufa</city>
        <state>Bashkortostan Republic</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petrozavodsk</city>
        <state>Karelia Republic</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <state>Tatarstan Republic</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site D</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site SM</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site ST</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site B</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site Z</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladimir</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site E</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site S</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruna</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site G</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chernivtsi</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site A</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site B</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site P</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site C</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site N</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site G</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site Sh</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site St</name>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 17, 2015</study_first_submitted>
  <study_first_submitted_qc>March 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2015</study_first_posted>
  <results_first_submitted>January 18, 2019</results_first_submitted>
  <results_first_submitted_qc>March 1, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2019</results_first_posted>
  <last_update_submitted>March 1, 2019</last_update_submitted>
  <last_update_submitted_qc>March 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid</keyword>
  <keyword>Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02405780/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/80/NCT02405780/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FKB327-FKB327-FKB327</title>
          <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327; (F-F-F).</description>
        </group>
        <group group_id="P2">
          <title>FKB327-Humira-FKB327</title>
          <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product, Humira, during Period I of study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327; (F-H-F).</description>
        </group>
        <group group_id="P3">
          <title>Humira-FKB327-FKB327</title>
          <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327; (H-F-F).</description>
        </group>
        <group group_id="P4">
          <title>Humira-Humira-FKB327</title>
          <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327; (H-H-F).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period I</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="216"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening Failure</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study procedures</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period II</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="189"/>
                <participants group_id="P2" count="100"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="174"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="81"/>
                <participants group_id="P4" count="172"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study procedures</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FKB327-FKB327</title>
          <description>This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003.</description>
        </group>
        <group group_id="B2">
          <title>FKB327-Humira</title>
          <description>This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003.</description>
        </group>
        <group group_id="B3">
          <title>Humira-FKB327</title>
          <description>This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003.</description>
        </group>
        <group group_id="B4">
          <title>Humira-Humira</title>
          <description>This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="216"/>
            <count group_id="B2" value="108"/>
            <count group_id="B3" value="108"/>
            <count group_id="B4" value="213"/>
            <count group_id="B5" value="645"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="169"/>
                    <measurement group_id="B5" value="540"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="171"/>
                    <measurement group_id="B5" value="501"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="185"/>
                    <measurement group_id="B5" value="552"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="39"/>
                    <measurement group_id="B5" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events as a Measure of Safety Per Treatment Group in Period I</title>
        <description>Period I: Patients were carefully monitor for Adverse Events from signing of informed consent until week 30 and thereafter during Period II of the study. For patients who discontinued early, a follow-up period of 4 weeks was added to the Early Termination Visit.
The investigator actively asked the patients for Adverse Events. Patients spontaneously reported Adverse Events to the Investigator during clinic visits or in between visits.</description>
        <time_frame>Period I: from Week 0 up until Week 30;</time_frame>
        <population>Each patient was counted once within each System Organ Class (SOC) and Preferred Term (PT). A patient may have had multiple events counted. Treatment Emergen Adverse Events (TEAE) defined as AEs that started or increased in severity after the first study dose and counted under the treatment arm.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product, Humira, during Period I of study FKB327-003 (F-H).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events as a Measure of Safety Per Treatment Group in Period I</title>
          <description>Period I: Patients were carefully monitor for Adverse Events from signing of informed consent until week 30 and thereafter during Period II of the study. For patients who discontinued early, a follow-up period of 4 weeks was added to the Early Termination Visit.
The investigator actively asked the patients for Adverse Events. Patients spontaneously reported Adverse Events to the Investigator during clinic visits or in between visits.</description>
          <population>Each patient was counted once within each System Organ Class (SOC) and Preferred Term (PT). A patient may have had multiple events counted. Treatment Emergen Adverse Events (TEAE) defined as AEs that started or increased in severity after the first study dose and counted under the treatment arm.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="59"/>
                    <measurement group_id="O4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 treatment related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature Discontinuation due to a TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Interruption due to a TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Adverse Events as a Measure of Safety in Period II - Single Treatment Period</title>
        <description>From week 30 all subjects were transferred to receive FKB327 treatment. Adverse Events were contentiously monitored and recorded during Period II. For patients discontinuing the study prematurely, a follow-up period of 4 weeks was added to the Early Termination Visit. The data for Period II is based on the number of patients in the Safety Analysis Set that entered Period II.</description>
        <time_frame>Period II: from Week 30 up to Week 80</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FKB327</title>
            <description>Period II: From week 30 all patients received one subcutaneous injection every other week of 40 mg/0.8 mL presented in an auto-injector (AI) or in a pre-filled syringe (PFS).
Based on the design of the study and to what treatment groups the subjects were randomised to in Period I, some patients received continuous treatment with FKB327 40 mg/0.8mL every other week by subcutaneous injection for up to 76 weeks. This was applicable to subjects in treatment groups (F-F-F) and (H-F-F)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Adverse Events as a Measure of Safety in Period II - Single Treatment Period</title>
          <description>From week 30 all subjects were transferred to receive FKB327 treatment. Adverse Events were contentiously monitored and recorded during Period II. For patients discontinuing the study prematurely, a follow-up period of 4 weeks was added to the Early Termination Visit. The data for Period II is based on the number of patients in the Safety Analysis Set that entered Period II.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 treatment related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Premature Discontinuation due to a TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Interruption due to a TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Serious Adverse Events as a Measure of Safety Per Treatment Group in Period I</title>
        <description>A Serious Adverse Event (SAE) was defined in the Protocol as: Death; or a Life-threatening Adverse Event (AE); Inpatient Hospitalization; Persistant or significant disability or incapacity; A congenital anomaly/birth defect; An important medical event that may not have resulted in death, have been life-threatening, or required hospitalization, but may have jeopardized the patient and may have required medical intervention to prevent 1 of the outcomes listed in this definition.
SAEs were followed until resolution, the investigator confirmed the event was unlikely to resolve or the patient was recorded as lost to follow-up.</description>
        <time_frame>Period I: from Week 0 up until Week 30</time_frame>
        <population>Each patient was counted once within each System Organ Class (SOC) and Preferred Term (PT). Death defined as a fatal outcome of a (S) AE.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product, Humira, during Period I of study FKB327-003 (F-H).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Adverse Events as a Measure of Safety Per Treatment Group in Period I</title>
          <description>A Serious Adverse Event (SAE) was defined in the Protocol as: Death; or a Life-threatening Adverse Event (AE); Inpatient Hospitalization; Persistant or significant disability or incapacity; A congenital anomaly/birth defect; An important medical event that may not have resulted in death, have been life-threatening, or required hospitalization, but may have jeopardized the patient and may have required medical intervention to prevent 1 of the outcomes listed in this definition.
SAEs were followed until resolution, the investigator confirmed the event was unlikely to resolve or the patient was recorded as lost to follow-up.</description>
          <population>Each patient was counted once within each System Organ Class (SOC) and Preferred Term (PT). Death defined as a fatal outcome of a (S) AE.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Discontinuation due to a TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Interruption due to a TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Serious Adverse Events as a Measure of Safety in Period II - Single Treatment Period</title>
        <description>Period II: at week 30 all patients were transferred to receive FKB327.
Each subject was counted once within each System Organ Class (SOC) and Preferred Term (PT). Death defined as a fatal outcome of a (S)AE.
SAEs were followed until resolution, the investigator confirmed the event was unlikely to resolve or the patient was lost to follow-up.</description>
        <time_frame>Period II: from Week 30 up to Week 80</time_frame>
        <population>Each patient was counted once within each System Organ Class (SOC) and Preferred Term (PT). Death defined as a fatal outcome of a (S) AE.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327</title>
            <description>Period II: From week 30 all subjects received one subcutaneous injection every other week of FKB327 40 mg/0.8 mL presented in an auto-injector (AI) or in a pre-filled syringe (PFS) .
Based on the design of the study and to what treatment groups the subjects were randomised to in Period I, some patients received continuous treatment with FKB327 40 mg/0.8mL every other week by subcutaneous injection for up to 76 weeks. This was applicable to subjects in treatment groups (F-F-F) and (H-F-F)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Adverse Events as a Measure of Safety in Period II - Single Treatment Period</title>
          <description>Period II: at week 30 all patients were transferred to receive FKB327.
Each subject was counted once within each System Organ Class (SOC) and Preferred Term (PT). Death defined as a fatal outcome of a (S)AE.
SAEs were followed until resolution, the investigator confirmed the event was unlikely to resolve or the patient was lost to follow-up.</description>
          <population>Each patient was counted once within each System Organ Class (SOC) and Preferred Term (PT). Death defined as a fatal outcome of a (S) AE.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Emergent Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 severe TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Discontinuation due to a TESEA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Interruption due to a TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of TESAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least 1 SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Vital Signs as a Measure of Safety - Systolic Blood Pressure</title>
        <description>Systolic Blood Pressure is part of Vital Signs which were part of the subject safety evaluations. Systolic Blood Pressure was measured at the following time-points: Week 0, Week 4, Week 8, Week 12, Week 24 and Week 80/End o Study (EOS). Systolic Blood Pressure with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visit is the number of patients who at a given timepoint had a measurement completed for the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs as a Measure of Safety - Systolic Blood Pressure</title>
          <description>Systolic Blood Pressure is part of Vital Signs which were part of the subject safety evaluations. Systolic Blood Pressure was measured at the following time-points: Week 0, Week 4, Week 8, Week 12, Week 24 and Week 80/End o Study (EOS). Systolic Blood Pressure with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
          <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visit is the number of patients who at a given timepoint had a measurement completed for the Safety Analysis Set.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_002</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" lower_limit="86" upper_limit="168"/>
                    <measurement group_id="O2" value="125.5" lower_limit="94" upper_limit="174"/>
                    <measurement group_id="O3" value="131.0" lower_limit="88" upper_limit="167"/>
                    <measurement group_id="O4" value="129.0" lower_limit="90" upper_limit="162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" lower_limit="84" upper_limit="166"/>
                    <measurement group_id="O2" value="123.5" lower_limit="90" upper_limit="160"/>
                    <measurement group_id="O3" value="127.0" lower_limit="98" upper_limit="179"/>
                    <measurement group_id="O4" value="125.0" lower_limit="90" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-34" upper_limit="35"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-30" upper_limit="32"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-44" upper_limit="32"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-50" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" lower_limit="82" upper_limit="172"/>
                    <measurement group_id="O2" value="125.0" lower_limit="95" upper_limit="164"/>
                    <measurement group_id="O3" value="124.0" lower_limit="92" upper_limit="186"/>
                    <measurement group_id="O4" value="125" lower_limit="94" upper_limit="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-56" upper_limit="38"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-22" upper_limit="44"/>
                    <measurement group_id="O3" value="-6.0" lower_limit="-39" upper_limit="39"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-37" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.0" lower_limit="88" upper_limit="154"/>
                    <measurement group_id="O2" value="124.0" lower_limit="89" upper_limit="153"/>
                    <measurement group_id="O3" value="128.0" lower_limit="92" upper_limit="160"/>
                    <measurement group_id="O4" value="125.0" lower_limit="92" upper_limit="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-47" upper_limit="32"/>
                    <measurement group_id="O2" value="-0.5" lower_limit="-28" upper_limit="41"/>
                    <measurement group_id="O3" value="-1.5" lower_limit="-35" upper_limit="30"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-38" upper_limit="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" lower_limit="91" upper_limit="159"/>
                    <measurement group_id="O2" value="124.5" lower_limit="86" upper_limit="165"/>
                    <measurement group_id="O3" value="126.0" lower_limit="89" upper_limit="167"/>
                    <measurement group_id="O4" value="125.0" lower_limit="92" upper_limit="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-35" upper_limit="45"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-40" upper_limit="35"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-44" upper_limit="28"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-46" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125.0" lower_limit="90" upper_limit="155"/>
                    <measurement group_id="O2" value="127.5" lower_limit="92" upper_limit="156"/>
                    <measurement group_id="O3" value="125.0" lower_limit="86" upper_limit="163"/>
                    <measurement group_id="O4" value="126.0" lower_limit="94" upper_limit="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-46" upper_limit="36"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-38" upper_limit="33"/>
                    <measurement group_id="O3" value="-5.0" lower_limit="-44" upper_limit="28"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-49" upper_limit="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.0" lower_limit="90" upper_limit="157"/>
                    <measurement group_id="O2" value="125.0" lower_limit="88" upper_limit="171"/>
                    <measurement group_id="O3" value="126.0" lower_limit="91" upper_limit="163"/>
                    <measurement group_id="O4" value="125.0" lower_limit="98" upper_limit="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-53" upper_limit="53"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-37" upper_limit="41"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-47" upper_limit="27"/>
                    <measurement group_id="O4" value="-1.5" lower_limit="-42" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Vital Signs as a Measure of Safety - Diastolic Blood Pressure</title>
        <description>Diastolic Blood Pressure is part of Vital Signs which were part of the subject safety evaluations. Diastolic Blood Pressure was measured at the following time-points: Week 0, Week 4, Week 8, Week 12, Week 24 and Week 80/End o Study (EOS). Diastolic Blood Pressure with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit measured.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visit is the number of patients who at a given timepoint had a measurement completed for the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs as a Measure of Safety - Diastolic Blood Pressure</title>
          <description>Diastolic Blood Pressure is part of Vital Signs which were part of the subject safety evaluations. Diastolic Blood Pressure was measured at the following time-points: Week 0, Week 4, Week 8, Week 12, Week 24 and Week 80/End o Study (EOS). Diastolic Blood Pressure with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit measured.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
          <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visit is the number of patients who at a given timepoint had a measurement completed for the Safety Analysis Set.</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_002</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="48" upper_limit="99"/>
                    <measurement group_id="O2" value="78.0" lower_limit="56" upper_limit="98"/>
                    <measurement group_id="O3" value="80.0" lower_limit="54" upper_limit="96"/>
                    <measurement group_id="O4" value="77.0" lower_limit="55" upper_limit="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="49" upper_limit="94"/>
                    <measurement group_id="O2" value="75.0" lower_limit="53" upper_limit="102"/>
                    <measurement group_id="O3" value="77.0" lower_limit="57" upper_limit="108"/>
                    <measurement group_id="O4" value="76.0" lower_limit="50" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-23" upper_limit="28"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-25" upper_limit="22"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-25" upper_limit="24"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-31" upper_limit="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="51" upper_limit="94"/>
                    <measurement group_id="O2" value="77.0" lower_limit="59" upper_limit="96"/>
                    <measurement group_id="O3" value="76.0" lower_limit="58" upper_limit="107"/>
                    <measurement group_id="O4" value="78.0" lower_limit="55" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-33" upper_limit="28"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-18" upper_limit="36"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-22" upper_limit="25"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-27" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="59" upper_limit="97"/>
                    <measurement group_id="O2" value="78.0" lower_limit="58" upper_limit="99"/>
                    <measurement group_id="O3" value="80.0" lower_limit="57" upper_limit="97"/>
                    <measurement group_id="O4" value="77.0" lower_limit="51" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-26" upper_limit="26"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-23" upper_limit="34"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-18" upper_limit="15"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-30" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="52" upper_limit="98"/>
                    <measurement group_id="O2" value="78.5" lower_limit="56" upper_limit="104"/>
                    <measurement group_id="O3" value="80.0" lower_limit="58" upper_limit="103"/>
                    <measurement group_id="O4" value="78.0" lower_limit="58" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-26" upper_limit="23"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-24" upper_limit="21"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-15" upper_limit="31"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-26" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="52" upper_limit="96"/>
                    <measurement group_id="O2" value="78.0" lower_limit="52" upper_limit="99"/>
                    <measurement group_id="O3" value="78.0" lower_limit="50" upper_limit="104"/>
                    <measurement group_id="O4" value="78.0" lower_limit="55" upper_limit="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-22" upper_limit="25"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-24" upper_limit="19"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-22" upper_limit="16"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-36" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" lower_limit="41" upper_limit="98"/>
                    <measurement group_id="O2" value="79.0" lower_limit="60" upper_limit="100"/>
                    <measurement group_id="O3" value="80.0" lower_limit="56" upper_limit="102"/>
                    <measurement group_id="O4" value="77.0" lower_limit="50" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-42" upper_limit="30"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-32" upper_limit="24"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-25" upper_limit="18"/>
                    <measurement group_id="O4" value="0.0" lower_limit="-48" upper_limit="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Vital Signs as a Measure of Safety - Pulse Rate</title>
        <description>Pulse rate is part of Vital Signs which were part of the subject safety evaluations. Pulse rate was measured at the following time-points: Weeks 0, 4, 8, 12, 24 and 80/End of Study (EOS). Pulse Rate with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visits is the number of patients who at a given time point had a measurement completed for the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs as a Measure of Safety - Pulse Rate</title>
          <description>Pulse rate is part of Vital Signs which were part of the subject safety evaluations. Pulse rate was measured at the following time-points: Weeks 0, 4, 8, 12, 24 and 80/End of Study (EOS). Pulse Rate with changes from Baseline_002 (NCT022600791) was summarized by treatment sequence over the whole study period for each visit.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administered at Week 0 from Study FKB327-002.</description>
          <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visits is the number of patients who at a given time point had a measurement completed for the Safety Analysis Set.</population>
          <units>Beats per minute (bpm)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_002</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" lower_limit="51" upper_limit="100"/>
                    <measurement group_id="O2" value="74.0" lower_limit="54" upper_limit="97"/>
                    <measurement group_id="O3" value="74.0" lower_limit="54" upper_limit="102"/>
                    <measurement group_id="O4" value="74.0" lower_limit="53" upper_limit="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="50" upper_limit="102"/>
                    <measurement group_id="O2" value="71.0" lower_limit="48" upper_limit="94"/>
                    <measurement group_id="O3" value="72.0" lower_limit="53" upper_limit="110"/>
                    <measurement group_id="O4" value="72.0" lower_limit="42" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-32" upper_limit="28"/>
                    <measurement group_id="O2" value="-3.0" lower_limit="-28" upper_limit="24"/>
                    <measurement group_id="O3" value="-3.0" lower_limit="-23" upper_limit="44"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-36" upper_limit="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="47" upper_limit="112"/>
                    <measurement group_id="O2" value="72.0" lower_limit="52" upper_limit="94"/>
                    <measurement group_id="O3" value="74.0" lower_limit="51" upper_limit="105"/>
                    <measurement group_id="O4" value="72.0" lower_limit="50" upper_limit="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-29" upper_limit="24"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-28" upper_limit="24"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-24" upper_limit="30"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-37" upper_limit="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="53" upper_limit="99"/>
                    <measurement group_id="O2" value="72.0" lower_limit="54" upper_limit="102"/>
                    <measurement group_id="O3" value="72.0" lower_limit="53" upper_limit="100"/>
                    <measurement group_id="O4" value="72" lower_limit="46" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-41" upper_limit="26"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-26" upper_limit="32"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-28" upper_limit="19"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-37" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" lower_limit="50" upper_limit="98"/>
                    <measurement group_id="O2" value="72.0" lower_limit="56" upper_limit="100"/>
                    <measurement group_id="O3" value="72.0" lower_limit="57" upper_limit="97"/>
                    <measurement group_id="O4" value="71.0" lower_limit="52" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" lower_limit="-36" upper_limit="30"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-31" upper_limit="18"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-28" upper_limit="25"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-30" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" lower_limit="50" upper_limit="103"/>
                    <measurement group_id="O2" value="72.0" lower_limit="55" upper_limit="96"/>
                    <measurement group_id="O3" value="72.0" lower_limit="58" upper_limit="99"/>
                    <measurement group_id="O4" value="72.0" lower_limit="49" upper_limit="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-35" upper_limit="26"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-33" upper_limit="20"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-29" upper_limit="26"/>
                    <measurement group_id="O4" value="-2.0" lower_limit="-32" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0" lower_limit="52" upper_limit="110"/>
                    <measurement group_id="O2" value="72.0" lower_limit="55" upper_limit="94"/>
                    <measurement group_id="O3" value="72.0" lower_limit="50" upper_limit="96"/>
                    <measurement group_id="O4" value="73.5" lower_limit="45" upper_limit="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-31" upper_limit="32"/>
                    <measurement group_id="O2" value="-2.0" lower_limit="-30" upper_limit="19"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-25" upper_limit="26"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-37" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in Vital Signs as a Measure of Safety - Temperature Measurements</title>
        <description>Temperature measurements forms part of the vital signs which was one of the continuous safety measurements for the study primary endpoint.
Temperature was measured at week 0, week 4, week 8, week 12, week 24 and at week 80 or at End of Study (EOS).
Temperature with change from Baseline_002 were summarized by treatment sequence over the whole study period.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administration at Week 0 from Study FKB327-002 (NCT02260791).</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visits is the number of patients who at a given timepoint had a measurement completed for the Safety Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Vital Signs as a Measure of Safety - Temperature Measurements</title>
          <description>Temperature measurements forms part of the vital signs which was one of the continuous safety measurements for the study primary endpoint.
Temperature was measured at week 0, week 4, week 8, week 12, week 24 and at week 80 or at End of Study (EOS).
Temperature with change from Baseline_002 were summarized by treatment sequence over the whole study period.
Baseline_002 is defined as the last non-missing measurement collected prior to the first study medication administration at Week 0 from Study FKB327-002 (NCT02260791).</description>
          <population>The number of patients in the Safety Analysis Set; is equal to the number of patients who entered Period I. The number of patients at the following visits is the number of patients who at a given timepoint had a measurement completed for the Safety Analysis Set.</population>
          <units>Centigrades</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_002</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.600" lower_limit="35.61" upper_limit="37.20"/>
                    <measurement group_id="O2" value="36.600" lower_limit="35.50" upper_limit="37.00"/>
                    <measurement group_id="O3" value="36.600" lower_limit="35.60" upper_limit="37.30"/>
                    <measurement group_id="O4" value="36.500" lower_limit="35.60" upper_limit="37.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.500" lower_limit="35.70" upper_limit="37.20"/>
                    <measurement group_id="O2" value="36.500" lower_limit="35.50" upper_limit="37.10"/>
                    <measurement group_id="O3" value="36.600" lower_limit="35.56" upper_limit="37.20"/>
                    <measurement group_id="O4" value="36.500" lower_limit="35.70" upper_limit="37.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.80" upper_limit="1.19"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-1.20" upper_limit="0.70"/>
                    <measurement group_id="O3" value="0.000" lower_limit="-0.70" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.000" lower_limit="-1.00" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.500" lower_limit="34.56" upper_limit="37.70"/>
                    <measurement group_id="O2" value="36.500" lower_limit="35.70" upper_limit="37.00"/>
                    <measurement group_id="O3" value="36.500" lower_limit="35.20" upper_limit="37.11"/>
                    <measurement group_id="O4" value="36.500" lower_limit="35.60" upper_limit="37.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="213"/>
                    <count group_id="O2" value="106"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-1.94" upper_limit="1.40"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.70" upper_limit="1.20"/>
                    <measurement group_id="O3" value="-0.100" lower_limit="-1.20" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.000" lower_limit="-1.20" upper_limit="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.500" lower_limit="35.00" upper_limit="37.28"/>
                    <measurement group_id="O2" value="36.500" lower_limit="35.40" upper_limit="37.20"/>
                    <measurement group_id="O3" value="36.500" lower_limit="35.60" upper_limit="37.20"/>
                    <measurement group_id="O4" value="36.500" lower_limit="35.50" upper_limit="37.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-1.50" upper_limit="1.19"/>
                    <measurement group_id="O2" value="-0.100" lower_limit="-0.83" upper_limit="1.10"/>
                    <measurement group_id="O3" value="-0.025" lower_limit="-0.70" upper_limit="0.80"/>
                    <measurement group_id="O4" value="0.000" lower_limit="-1.40" upper_limit="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.500" lower_limit="35.56" upper_limit="37.20"/>
                    <measurement group_id="O2" value="36.500" lower_limit="35.10" upper_limit="37.10"/>
                    <measurement group_id="O3" value="36.500" lower_limit="35.40" upper_limit="37.00"/>
                    <measurement group_id="O4" value="36.500" lower_limit="35.60" upper_limit="37.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-0.94" upper_limit="0.80"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-1.10" upper_limit="0.80"/>
                    <measurement group_id="O3" value="-0.100" lower_limit="-1.10" upper_limit="0.90"/>
                    <measurement group_id="O4" value="0.000" lower_limit="-1.60" upper_limit="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.500" lower_limit="35.50" upper_limit="37.20"/>
                    <measurement group_id="O2" value="36.500" lower_limit="35.50" upper_limit="37.90"/>
                    <measurement group_id="O3" value="36.500" lower_limit="35.60" upper_limit="37.40"/>
                    <measurement group_id="O4" value="36.500" lower_limit="35.60" upper_limit="37.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="198"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-1.00" upper_limit="1.00"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.90" upper_limit="1.40"/>
                    <measurement group_id="O3" value="0.000" lower_limit="-0.90" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.000" lower_limit="-1.10" upper_limit="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.500" lower_limit="35.60" upper_limit="37.30"/>
                    <measurement group_id="O2" value="36.500" lower_limit="35.70" upper_limit="37.10"/>
                    <measurement group_id="O3" value="36.500" lower_limit="35.30" upper_limit="37.00"/>
                    <measurement group_id="O4" value="36.500" lower_limit="35.50" upper_limit="37.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Changes from Baseline_002 at week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.000" lower_limit="-1.10" upper_limit="1.19"/>
                    <measurement group_id="O2" value="0.000" lower_limit="-0.80" upper_limit="0.90"/>
                    <measurement group_id="O3" value="-0.100" lower_limit="-1.00" upper_limit="0.70"/>
                    <measurement group_id="O4" value="0.000" lower_limit="-1.00" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Summary of Most Common Clinical Significant Laboratory Parameters Reported as Adverse Events (Reported by ≥1% of the Patients)</title>
        <description>Clinical Laboratory tests for hematology and serum chemistry were performed by the sites and analysed at a Central Laboratory. Urine dip-stick tests were performed by the sites. Laboratory samples were taken at the following time-points (weeks): 0; 4; 8; 12; 24; 30; 42; 54; 66; 76 and 80/End of Study (EOS). Each result outside its normal range was review and assessed by the investigator whether or not it was Clinically Significant (CS) or Not Clinically Significant (NCS) CS laboratory abnormalities were recorded as AEs.</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (F-H).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (H-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (H-H).</description>
          </group>
          <group group_id="O5">
            <title>FKB327 Period II</title>
            <description>From Week 30 all patients were treated with FKB327</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Most Common Clinical Significant Laboratory Parameters Reported as Adverse Events (Reported by ≥1% of the Patients)</title>
          <description>Clinical Laboratory tests for hematology and serum chemistry were performed by the sites and analysed at a Central Laboratory. Urine dip-stick tests were performed by the sites. Laboratory samples were taken at the following time-points (weeks): 0; 4; 8; 12; 24; 30; 42; 54; 66; 76 and 80/End of Study (EOS). Each result outside its normal range was review and assessed by the investigator whether or not it was Clinically Significant (CS) or Not Clinically Significant (NCS) CS laboratory abnormalities were recorded as AEs.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
                <count group_id="O5" value="572"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukopenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutropenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALT increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyslipidaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypercholesterolaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CRP increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Latent TB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mycobacterium tuberculosis complex test positive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Haematuria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Disease Activity Score 28 Based on C Reactive Protein (DAS28 CRP) Score Compared to Baseline as a Measure of Efficacy</title>
        <description>The DAS28 score is a combined index that has been developed to measure the disease activity in patients with Rheumatoid arthritis (RA) and has been extensively validated for the use in clinical studies. The DAS28-CRP assessment involved evaluating the number of tender (TJC) and the swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (Visual analogue scale (VAS) from 0-100, very well to extremely bad). The individual results are summarized using a formula. DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity.
During the FKB327-003 study for Period I and Period II the DAS28-CRP score was compared to Baseline in study FKB327-002 (NCT02260791).</description>
        <time_frame>From Week 0 of FKB327-002 to Week 80</time_frame>
        <population>DAS28-CRP and change from Baseline in Study FKB327-002 (i.e. Baseline_002) in DAS28-CRP were summarized by overall treatment sequence and visit as well as by treatment for each period (Period I and Period II)</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive FKB327 in Study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to receive the reference product Humira in Study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Disease Activity Score 28 Based on C Reactive Protein (DAS28 CRP) Score Compared to Baseline as a Measure of Efficacy</title>
          <description>The DAS28 score is a combined index that has been developed to measure the disease activity in patients with Rheumatoid arthritis (RA) and has been extensively validated for the use in clinical studies. The DAS28-CRP assessment involved evaluating the number of tender (TJC) and the swollen (SJC) joints (out of 28 specified joints), serum CRP, and patient global assessment of disease activity (Visual analogue scale (VAS) from 0-100, very well to extremely bad). The individual results are summarized using a formula. DAS28 is a number on a scale from 0 to 10 indicating the current activity of the patient's RA. A higher score indicates higher disease activity.
During the FKB327-003 study for Period I and Period II the DAS28-CRP score was compared to Baseline in study FKB327-002 (NCT02260791).</description>
          <population>DAS28-CRP and change from Baseline in Study FKB327-002 (i.e. Baseline_002) in DAS28-CRP were summarized by overall treatment sequence and visit as well as by treatment for each period (Period I and Period II)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline_002</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.02" lower_limit="3.3" upper_limit="8.1"/>
                    <measurement group_id="O2" value="6.12" lower_limit="2.9" upper_limit="8.5"/>
                    <measurement group_id="O3" value="5.99" lower_limit="3.7" upper_limit="7.9"/>
                    <measurement group_id="O4" value="6.11" lower_limit="4.0" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" lower_limit="1.2" upper_limit="7.3"/>
                    <measurement group_id="O2" value="3.49" lower_limit="1.2" upper_limit="7.4"/>
                    <measurement group_id="O3" value="3.65" lower_limit="1.2" upper_limit="7.2"/>
                    <measurement group_id="O4" value="3.36" lower_limit="1.2" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="214"/>
                    <count group_id="O2" value="107"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.56" lower_limit="-5.7" upper_limit="1.0"/>
                    <measurement group_id="O2" value="-2.63" lower_limit="-6.4" upper_limit="1.2"/>
                    <measurement group_id="O3" value="-2.33" lower_limit="-5.4" upper_limit="0.9"/>
                    <measurement group_id="O4" value="-2.75" lower_limit="-5.7" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="105"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="1.2" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.37" lower_limit="1.2" upper_limit="7.0"/>
                    <measurement group_id="O3" value="3.53" lower_limit="1.3" upper_limit="6.7"/>
                    <measurement group_id="O4" value="3.29" lower_limit="1.2" upper_limit="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="207"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="105"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.64" lower_limit="-6.1" upper_limit="1.8"/>
                    <measurement group_id="O2" value="-2.76" lower_limit="-6.9" upper_limit="0.9"/>
                    <measurement group_id="O3" value="-2.48" lower_limit="-4.9" upper_limit="1.6"/>
                    <measurement group_id="O4" value="-2.81" lower_limit="-6.1" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" lower_limit="1.2" upper_limit="7.2"/>
                    <measurement group_id="O2" value="3.37" lower_limit="1.2" upper_limit="6.9"/>
                    <measurement group_id="O3" value="3.51" lower_limit="1.2" upper_limit="6.6"/>
                    <measurement group_id="O4" value="3.25" lower_limit="1.2" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="201"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.72" lower_limit="-5.9" upper_limit="2.7"/>
                    <measurement group_id="O2" value="-2.74" lower_limit="-6.9" upper_limit="0.8"/>
                    <measurement group_id="O3" value="-2.47" lower_limit="-4.8" upper_limit="0.9"/>
                    <measurement group_id="O4" value="-2.84" lower_limit="-5.8" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" lower_limit="1.2" upper_limit="6.9"/>
                    <measurement group_id="O2" value="3.30" lower_limit="1.2" upper_limit="7.1"/>
                    <measurement group_id="O3" value="3.40" lower_limit="1.3" upper_limit="6.2"/>
                    <measurement group_id="O4" value="3.21" lower_limit="1.2" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="199"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.70" lower_limit="-5.9" upper_limit="0.8"/>
                    <measurement group_id="O2" value="-2.80" lower_limit="-6.9" upper_limit="0.3"/>
                    <measurement group_id="O3" value="-2.57" lower_limit="-4.9" upper_limit="0.5"/>
                    <measurement group_id="O4" value="-2.88" lower_limit="-5.8" upper_limit="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" lower_limit="1.2" upper_limit="7.8"/>
                    <measurement group_id="O2" value="3.27" lower_limit="1.2" upper_limit="7.1"/>
                    <measurement group_id="O3" value="3.40" lower_limit="1.2" upper_limit="7.7"/>
                    <measurement group_id="O4" value="3.07" lower_limit="1.2" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="196"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.89" lower_limit="-6.1" upper_limit="1.3"/>
                    <measurement group_id="O2" value="-2.86" lower_limit="-6.7" upper_limit="0.9"/>
                    <measurement group_id="O3" value="-2.57" lower_limit="-5.4" upper_limit="1.7"/>
                    <measurement group_id="O4" value="-3.04" lower_limit="-6.0" upper_limit="-0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period II: Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="1.2" upper_limit="7.1"/>
                    <measurement group_id="O2" value="3.28" lower_limit="1.2" upper_limit="7.1"/>
                    <measurement group_id="O3" value="3.20" lower_limit="1.3" upper_limit="6.3"/>
                    <measurement group_id="O4" value="3.13" lower_limit="1.2" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="182"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" lower_limit="-6.1" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-2.84" lower_limit="-6.6" upper_limit="0.5"/>
                    <measurement group_id="O3" value="-2.78" lower_limit="-5.3" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-2.95" lower_limit="-6.2" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.05" lower_limit="1.2" upper_limit="6.8"/>
                    <measurement group_id="O2" value="3.28" lower_limit="1.2" upper_limit="6.1"/>
                    <measurement group_id="O3" value="3.08" lower_limit="1.3" upper_limit="6.0"/>
                    <measurement group_id="O4" value="3.07" lower_limit="1.2" upper_limit="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 42 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="183"/>
                    <count group_id="O2" value="95"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.97" lower_limit="-5.6" upper_limit="0.9"/>
                    <measurement group_id="O2" value="-2.83" lower_limit="-6.2" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-2.88" lower_limit="-5.5" upper_limit="-0.0"/>
                    <measurement group_id="O4" value="-3.01" lower_limit="-5.8" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" lower_limit="1.2" upper_limit="7.5"/>
                    <measurement group_id="O2" value="3.22" lower_limit="1.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="3.26" lower_limit="1.2" upper_limit="6.2"/>
                    <measurement group_id="O4" value="2.96" lower_limit="1.2" upper_limit="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.99" lower_limit="-5.9" upper_limit="0.4"/>
                    <measurement group_id="O2" value="-2.90" lower_limit="-6.2" upper_limit="0.9"/>
                    <measurement group_id="O3" value="-2.70" lower_limit="-5.4" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-3.12" lower_limit="-5.6" upper_limit="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" lower_limit="1.2" upper_limit="7.0"/>
                    <measurement group_id="O2" value="3.17" lower_limit="1.2" upper_limit="5.7"/>
                    <measurement group_id="O3" value="3.09" lower_limit="1.3" upper_limit="5.6"/>
                    <measurement group_id="O4" value="2.91" lower_limit="1.2" upper_limit="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.09" lower_limit="-5.9" upper_limit="0.3"/>
                    <measurement group_id="O2" value="-2.96" lower_limit="-6.9" upper_limit="-0.0"/>
                    <measurement group_id="O3" value="-2.83" lower_limit="-5.5" upper_limit="0.8"/>
                    <measurement group_id="O4" value="-3.15" lower_limit="-5.6" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.97" lower_limit="1.2" upper_limit="7.8"/>
                    <measurement group_id="O2" value="3.02" lower_limit="1.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="3.12" lower_limit="1.3" upper_limit="7.0"/>
                    <measurement group_id="O4" value="2.94" lower_limit="1.2" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.04" lower_limit="-5.9" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-3.11" lower_limit="-6.1" upper_limit="0.4"/>
                    <measurement group_id="O3" value="-2.79" lower_limit="-5.5" upper_limit="1.0"/>
                    <measurement group_id="O4" value="-3.14" lower_limit="-5.7" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" lower_limit="1.2" upper_limit="7.1"/>
                    <measurement group_id="O2" value="3.09" lower_limit="1.2" upper_limit="6.9"/>
                    <measurement group_id="O3" value="3.25" lower_limit="1.2" upper_limit="6.7"/>
                    <measurement group_id="O4" value="3.06" lower_limit="1.2" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80 change from Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" lower_limit="-6.2" upper_limit="2.2"/>
                    <measurement group_id="O2" value="-3.05" lower_limit="-6.9" upper_limit="-0.3"/>
                    <measurement group_id="O3" value="-2.66" lower_limit="-5.4" upper_limit="0.2"/>
                    <measurement group_id="O4" value="-3.02" lower_limit="-5.8" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 20 (ACR20) Response Rates From Baseline as a Measure of Efficacy</title>
        <description>An ACR20 response means that the patient achieved a 20% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and a 20% improvement in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein, CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>Number of patients at a given time-point with an observed ACR20 score defined as a 20% improvement in tender and swollen joints and at least 3 out of 5 other indicators from Baseline_002 (Week 0 of FKB327-002; NCT02260791)</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product, Humira, during Period I of study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 20 (ACR20) Response Rates From Baseline as a Measure of Efficacy</title>
          <description>An ACR20 response means that the patient achieved a 20% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and a 20% improvement in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein, CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
          <population>Number of patients at a given time-point with an observed ACR20 score defined as a 20% improvement in tender and swollen joints and at least 3 out of 5 other indicators from Baseline_002 (Week 0 of FKB327-002; NCT02260791)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="87"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="210"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="173"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="89"/>
                    <measurement group_id="O3" value="82"/>
                    <measurement group_id="O4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period II: Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="79"/>
                    <measurement group_id="O4" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="79"/>
                    <measurement group_id="O3" value="81"/>
                    <measurement group_id="O4" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="78"/>
                    <measurement group_id="O3" value="77"/>
                    <measurement group_id="O4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="71"/>
                    <measurement group_id="O4" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="62"/>
                    <measurement group_id="O4" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 50 (ACR50) Response Rates From Baseline as a Measure of Efficacy</title>
        <description>An ACR50 response means that the patient achieved a 50% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein, CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>Number of patients at a given time-point with an observed ACR50 score defined as a 50% improvement in tender and swollen joints and at least in 3 out of 5 other indicators from Baseline_002 (Week 0 of FKB327-002; NCT02260791)</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product, Humira, during Period I of study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 50 (ACR50) Response Rates From Baseline as a Measure of Efficacy</title>
          <description>An ACR50 response means that the patient achieved a 50% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein, CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
          <population>Number of patients at a given time-point with an observed ACR50 score defined as a 50% improvement in tender and swollen joints and at least in 3 out of 5 other indicators from Baseline_002 (Week 0 of FKB327-002; NCT02260791)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="215"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="208"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="52"/>
                    <measurement group_id="O4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="205"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="51"/>
                    <measurement group_id="O4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period II: Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="50"/>
                    <measurement group_id="O4" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="44"/>
                    <measurement group_id="O4" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="43"/>
                    <measurement group_id="O4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>American College of Rheumatology 70 (ACR70) Response Rates From Baseline as a Measure of Efficacy</title>
        <description>An ACR70 response means that the patient achieved a 70% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein,CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>Number of patients at a given time-point with an observed ACR70 score defined as a 70% improvement in tender and swollen joints and at least 3 out of 5 other indicators from Baseline_002 (Week 0 of FKB327-002; NCT02260791)</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product, Humira, during Period I of study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>American College of Rheumatology 70 (ACR70) Response Rates From Baseline as a Measure of Efficacy</title>
          <description>An ACR70 response means that the patient achieved a 70% improvement in Tender Joint Count (TJC) and Swollen Joint Count (SJC) and in at least 3 of the other 5 Core Data Set elements listed below:
Acute phase reactant (C-reactive protein,CRP) A high level of CRP in the blood is a marker of inflammation.
Patient global assessment of disease activity assessed on a Visual Analog Scale (VAS) ranging from very well to extremely bad was assessed on a 100 point scale. (from 0 to 100)
Physician global assessment of disease activity assessed on a VAS ranging from very low to very high was assessed on 100 point scale
Patient pain scale assessed on a VAS ranging from very well to extremely bad was assessed on 100 point scale
Disability/functional questionnaire (patient completed Heath Assessment Questionnaire Disability Index (HAQ-DI)) A higher response rate is a better outcome. The minimum possible value is 0% and the maximum possible value is 100%</description>
          <population>Number of patients at a given time-point with an observed ACR70 score defined as a 70% improvement in tender and swollen joints and at least 3 out of 5 other indicators from Baseline_002 (Week 0 of FKB327-002; NCT02260791)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="211"/>
                    <count group_id="O2" value="104"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="204"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="104"/>
                    <count group_id="O4" value="204"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="203"/>
                    <count group_id="O2" value="102"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="203"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period II: Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="99"/>
                    <count group_id="O3" value="92"/>
                    <count group_id="O4" value="189"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="184"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="88"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Patients Developing Anti-drug Antibodies (ADAs)</title>
        <description>Blood samples for assessment of Anti-Drug antibodies (ADA) were collected prior to dosing (trough samples) at Baseline (Week 0) and at Weeks 12, 24, 30, 54, 76 and 80/EOS.
All ADA activity was listed and summarized for each treatment sequence by time point during the overall treatment period as well as by treatment group for each period (Period I and Period II). Descriptive statistics included absolute counts (n) and percentage (%).</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>Number of patients who had an assay result of positive Anti-Drug Antibodies at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product Humira during Period I of study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).
Period II: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Developing Anti-drug Antibodies (ADAs)</title>
          <description>Blood samples for assessment of Anti-Drug antibodies (ADA) were collected prior to dosing (trough samples) at Baseline (Week 0) and at Weeks 12, 24, 30, 54, 76 and 80/EOS.
All ADA activity was listed and summarized for each treatment sequence by time point during the overall treatment period as well as by treatment group for each period (Period I and Period II). Descriptive statistics included absolute counts (n) and percentage (%).</description>
          <population>Number of patients who had an assay result of positive Anti-Drug Antibodies at given time-points.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="216"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="108"/>
                <count group_id="O4" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="212"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="67"/>
                    <measurement group_id="O4" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="54"/>
                    <measurement group_id="O4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="96"/>
                    <count group_id="O4" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="47"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period II: Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="174"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80/EOS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Last Sampling Day</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="216"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="108"/>
                    <count group_id="O4" value="213"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Trough Adalimumab Concentration</title>
        <description>Blood samples for the quantification of adalimumab concentration in serum were collected prior to dosing (trough samples) at Baseline (Week 0), and at weeks 12, 24 , 30, 54, 76 and 80/EOS.</description>
        <time_frame>From Week 0 to Week 80</time_frame>
        <population>Analysis of Serum Concentration Data (ng/mL). Repeated measure of pharmacokinetic(s) (PK) trough concentrations at given time-points.</population>
        <group_list>
          <group group_id="O1">
            <title>FKB327-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study, FKB327-002 and were re-randomized to FKB327 in Period I of study FKB327-003 (F-F).
Period II: From week 30 all subjects received FKB327 (F-F-F).</description>
          </group>
          <group group_id="O2">
            <title>FKB327-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with FKB327 in the preceding study FKB327-002 and were re-randomized to the reference product, Humira, during Period I of study FKB327-003 (F-H).
Period II: From week 30 all subjects received FKB327 (F-H-F).</description>
          </group>
          <group group_id="O3">
            <title>Humira-FKB327-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002 and were re-randomized to FKB327 during Period I of study FKB327-003 (H-F).
Period II: From week 30 all subjects received FKB327 (H-F-F).</description>
          </group>
          <group group_id="O4">
            <title>Humira-Humira-FKB327</title>
            <description>Period I: This is the treatment arm where subjects had been treated with the reference product Humira in the preceding study, FKB327-002, and were re-randomized to the reference product Humira during Period I of study FKB327-003 (H-H).
Period I: From week 30 all subjects received FKB327 (H-H-F).</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Adalimumab Concentration</title>
          <description>Blood samples for the quantification of adalimumab concentration in serum were collected prior to dosing (trough samples) at Baseline (Week 0), and at weeks 12, 24 , 30, 54, 76 and 80/EOS.</description>
          <population>Analysis of Serum Concentration Data (ng/mL). Repeated measure of pharmacokinetic(s) (PK) trough concentrations at given time-points.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="208"/>
                <count group_id="O2" value="105"/>
                <count group_id="O3" value="107"/>
                <count group_id="O4" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="208"/>
                    <count group_id="O2" value="105"/>
                    <count group_id="O3" value="107"/>
                    <count group_id="O4" value="209"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6500" spread="4640"/>
                    <measurement group_id="O2" value="6000" spread="4520"/>
                    <measurement group_id="O3" value="5170" spread="3440"/>
                    <measurement group_id="O4" value="5720" spread="3470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="202"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="103"/>
                    <count group_id="O4" value="202"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6310" spread="4720"/>
                    <measurement group_id="O2" value="5380" spread="4150"/>
                    <measurement group_id="O3" value="6180" spread="3970"/>
                    <measurement group_id="O4" value="6010" spread="3730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="197"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="199"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5970" spread="4500"/>
                    <measurement group_id="O2" value="5100" spread="3990"/>
                    <measurement group_id="O3" value="6320" spread="4320"/>
                    <measurement group_id="O4" value="5950" spread="3750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Period II: Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="190"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6000" spread="4450"/>
                    <measurement group_id="O2" value="4790" spread="4290"/>
                    <measurement group_id="O3" value="5730" spread="3750"/>
                    <measurement group_id="O4" value="5750" spread="3680"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="181"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6090" spread="4620"/>
                    <measurement group_id="O2" value="5830" spread="4290"/>
                    <measurement group_id="O3" value="5840" spread="4100"/>
                    <measurement group_id="O4" value="6620" spread="3920"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="90"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6460" spread="4140"/>
                    <measurement group_id="O2" value="5900" spread="4020"/>
                    <measurement group_id="O3" value="6070" spread="4350"/>
                    <measurement group_id="O4" value="6730" spread="4080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="87"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4320" spread="3130"/>
                    <measurement group_id="O2" value="4000" spread="3280"/>
                    <measurement group_id="O3" value="4060" spread="3310"/>
                    <measurement group_id="O4" value="4520" spread="3100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Overall Adverse Events and Serious Adverse Events were collected and monitored up to week 80 for subjects completing the study and 4 weeks after an Early Termination Visit. Period I - from signing of informed consent up to week 30. During this period subjects received either FKB327 or the reference product Humira. Period II: From week 30 to week 76 all subjects received FKB327 hence the maximum duration of FKB327 treatment was about 2.5 times greater compared to the Humira (581 vs 222 days).</time_frame>
      <desc>The overall exposure in patient-years was nearly 4 times greater for FKB327 (673.7) compared to Humira (175.4), due to patients switching from Humira to FKB327 for Period II, which should be taken into account when reviewing the safety results where FKB327 and Humira are directly compared.</desc>
      <group_list>
        <group group_id="E1">
          <title>FKB327</title>
          <description>FKB327: Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg/0.8mL every 2 weeks for 28 weeks. From week 30 all patients were transferred to receive FKB327 40 mg/0.8 mL every other week presented in an auto-injector (AI) or a pre-filled syringe (PFS). Some patients received continuous FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Humira®</title>
          <description>Humira®: Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. From week 30 to week 76 all patients were transferred to receive FKB327 40 mg/0.8 mL in a pre-filled syringe (PFS) every other week by subcutaneous injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oesophageal rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Maternal exposure during pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Back disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anterior spinal artery syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Renal failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Joint surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Knee Arthroplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Synovectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphostatis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (17.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="125" subjects_at_risk="614"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="77" subjects_affected="68" subjects_at_risk="614"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="321"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="32" subjects_at_risk="614"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="53" subjects_affected="37" subjects_at_risk="614"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="321"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Investigator and Sponsor will discuss the preparation of a manuscript for publication in a peer reviewed journal or an abstract for presentation. Either party may undertake the task but both must agree to the strategy before work is started. Each party will allow the other 30 days to comment before any results are submitted for publication or presentation. Authorship should reflect work done by the Investigator an Sponsor, in accordance with recognized principles of scientific collaboration.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Information</name_or_title>
      <organization>Fujifilm Kyowa Kirin Biologics Co., Ltd., EU Branch</organization>
      <phone>0044 1896 668 173</phone>
      <email>Clinical-Trials@fk-b.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

